Trending...
- PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth
- HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies
- The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
JUPITER, Fla. - Michimich -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Michimich.com
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Michimich.com
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on Michimich.com
- Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met
- Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York"
- MoMojo Records announces posthumous album from Kip London
- Guests Can Save 20 Percent on a Florida Keys Vacation Home Rental with KeysCaribbean's 'Last-Minute Booking Discount'
- All-Woman Trial Team Wins Major Verdict in Major Case
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on Michimich.com
- Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
- Thrive Cannabis Marketplace Opens New Main Street Dispensary in Las Vegas Arts District
- ReferFriends.io Officially Launches: A New Global Hub for Sharing and Discovering Referral Codes
- Emerging Managers Podcast Launches, Highlighting New Players in Venture Capital Outperforming the Status Quo
- North American Security Launches New Website to Reflect Evolving Industry Demands and Client-Centered Solutions
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
Filed Under: Health
0 Comments
Latest on Michimich.com
- R&R Mechanical Services, LLC Expands Expert Furnace Repair Services in Grand Rapids, MI
- Hanon Systems Wins Third PACE Award for Visible-Light LED Photocatalyst Technology
- Coming Up on "Financial Freedom with Tom Hegna" Retirement Authority Daniel Rondberg from Nation's First Financial
- The Ten News Wins 2025 Ambie Award for Best News Podcast
- ServiceAgent.ai Brings 24/7 AI Call Answering to America's Home Services
- Jed the Fish, The Rapscallion of Los Angeles KROQ's Airwaves and Provocateur, Has Signed Off at 69
- New Website Uses A.I. To Help Readers Think All Of Your Books Into Existence
- Aries Industries Earns USA Today Top Workplaces Award, Honoring Company as Great Place to Work
- Revize Government Websites Launches Cutting-Edge AI Search Tool
- The most Googled celebrity divorces in the UK
- DABO Celebrates 46 Years of Service with Annual State of the Race Events
- HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies
- Fresh Water Ventures Acquires Dun-Rite Machining, Inc
- Strike School Unveils Bold New Rebrand with Innovative Educational Solutions for the 2025-2026 School Year
- The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
- Robinson earns fourth straight supplier award from Rolls-Royce
- PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth
- "Reflections of WEUSI 1965 – Present" The Intersection of Power, Art, and Wellness for Stress Awareness Month
- Blaming Patients: How Failed Treatments Fuel a $51 Billion Brain Device Industry
- Is Your Ride Feeling Rough? ArborMotion Urges Drivers to Check Alignment and Suspension Systems